The short answer
Discuss grapefruit with the cancer team while taking pirtobrutinib. A specific increase in drug exposure or toxicity from this exact product has not been established, and there is no validated spacing interval.
What this answer covers
Oral pirtobrutinib with grapefruit. Fruit, juice and unspecified extracts differ; tested CYP3A drug inhibition is not direct botanical evidence.
- Supplement or preparation
- Citrus paradisi
- Medication ingredient
- pirtobrutinib
Check the prescribed treatment
This review concerns oral pirtobrutinib tablets used for selected blood cancers. Pirtobrutinib is a reversible BTK inhibitor, and interaction findings or dose adjustments from other BTK medicines should not be copied to it. Keep your prescribed dosing and blood-count monitoring plan.
The measured interaction used a drug inhibitor
Pirtobrutinib exposure rose by about half with itraconazole in the label’s clinical study. Grapefruit was not the tested substance. Neither the same percentage nor a strong-inhibitor classification can be assigned to a fruit serving or an unspecified extract.
The significance of that increase is not uniform
Another current oral product document interprets the itraconazole exposure increase as not clinically meaningful and recommends no inhibitor-related dose adjustment. This difference reinforces the need to follow your prescribed product and care team, rather than copying a dose rule or assuming measured exposure always means toxicity.
Ask about the actual fruit product
Patient guidance specifically advises discussing grapefruit and juice with the prescriber. Bring the extract ingredients, amount and frequency if you use a supplement. Seed extracts, fruit extracts and juice are not interchangeable, and a few hours of separation has not been validated for this exact pair.
Evidence and practical considerations
Absorption & effectiveness
A practical grapefruit review is supported, but a universal exact-product exposure or toxicity assertion exceeds the checked evidence.
- Exact scope
- Oral pirtobrutinib with grapefruit. Fruit, juice and unspecified extracts differ; tested CYP3A drug inhibition is not direct botanical evidence. with RxNorm 2629338 IN pirtobrutinib. Exact current oral product: JAYPIRCA oral pirtobrutinib tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- No exact grapefruit/fruit-extract clinical study. Product information differs in interpretation of drug-inhibitor exposure; no botanical potency classification, toxicity rate or spacing.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Bleeding/cytopenia warnings; strong inhibitor AUC increase 49% and strong inducer reduction 71%; product-specific management.
How this applies: RxNorm 2629338 IN pirtobrutinib. Exact current oral product: JAYPIRCA oral pirtobrutinib tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Current original product information
medicines.org.uk · Source check Sep 11, 2026
Population: Patients prescribed pirtobrutinib.
Itraconazole raised AUC 48% without changing peak; considered not clinically meaningful in this product information, which recommends no inhibitor dose adjustment.
How this applies: Exact drug contrary interpretation retained, no patient-directed dose transfer.
US instructions differ; no grapefruit study or automatic botanical potency classification.
Source 3: Original official patient guidance
medlineplus.gov · Source check Sep 11, 2026
Population: Patients receiving pirtobrutinib.
Discuss grapefruit and juice with the prescriber.
How this applies: Exact drug practical guidance.
Product-review advice, not proof of exact extract exposure change or mandatory interval.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
pirtobrutinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 723ae4585a4d652c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.